Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matthew Sherman Insider Profile
4 Followers
Matthew Sherman, EVP & Chief Medical Officer at Acceleron Pharma, holds 20.00K shares in Pulmatrix (Ticker: PULM), holds 77.27K shares in Acceleron Pharma (Ticker: XLRN), holds ― shares in Lumos Pharma (Ticker: LUMO).
Matthew Sherman Acceleron Pharma (XLRN)EVP & Chief Medical Officer
Acceleron Pharma (XLRN)
EVP & Chief Medical Officer
Ranked #40,661 out of 98,501 Corporate Insiders
Profitable Transactions
8 out of 15 Profitable Transactions
Average Return
+0.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Matthew Sherman holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Feb 18, 2021 - Feb 18, 2022
Return:+82.30%
The most profitable trade made by Matthew Sherman
Matthew Sherman's Trading History
Acceleron Pharma
Apr 04, 2018
―
Uninformative Sell
176.77K
$13.81M
Pulmatrix
Apr 05, 2018
Director
Uninformative Buy
―
$41.80K
Lumos Pharma
―
Director
―
―
Pieris Pharmaceuticals
―
Director
―
―
Deciphera Pharmaceuticals
Feb 20, 2024
EVP & Chief Medical Officer
Uninformative Buy
―
$1.60M
List of latest transactions for each holding click on a transaction to see Matthew Sherman's performance on stock
You May Also Like
Matthew Sherman insider profile FAQ
What is the percentage of profitable transactions made by Matthew Sherman?
The percentage of profitable transactions made by Matthew Sherman is 53%.
What is the average return per transaction made by Matthew Sherman?
The average return per transaction made by Matthew Sherman is 0.60%.
What stocks does Matthew Sherman hold?
Matthew Sherman holds: XLRN, PULM, LUMO, PIRS, DCPH stocks.
What was Matthew Sherman’s latest transaction?
Matthew Sherman latest transaction was an Uninformative Buy of ―.
What was Matthew Sherman's most profitable transaction?
Matthew Sherman’s most profitable transaction was an Informative Sell of DCPH stock on February 18, 2021. The return on the trade was 82.30%.
What is Matthew Sherman's role in Acceleron Pharma?
Matthew Sherman's role in Acceleron Pharma is EVP & Chief Medical Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.